| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-01-15 | Medivation (USA - MA) OncoFusion Therapeutics (USA - MI) | compounds targeting Bromodomain and Extra-Terminal (BET) proteins | R&D licensing |
Cancer - Oncology | Termination of an agreement | |
| 2016-01-14 | Swedish Orphan Biovitrum - SOBI (Sweden) | Rare diseases | resignation |
Resignation | ||
| 2016-01-14 | Affimed (Germany) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-01-13 | Kite Pharma (USA - CA) Leiden University Medical Center (The Netherlands) | T cell receptor (TCR) product candidates | solid tumors associated with human papillomavirus type 16 (HPV16) infection | R&D licensing |
Cancer - Oncology - Infectious diseases | R&D agreement |
| 2016-01-13 | Lonza (Switzerland) | expansion of a production plant |
Technology - Services | Construction of a production plant | ||
| 2016-01-13 | Organovo (USA - CA) | Technology - Services | Establishment of a new subsidiary in the EU | |||
| 2016-01-13 | Oxford Biomedica (UK) | biomanufacturing facility for cell and gene therapy products | validation of a production plant |
Cancer - Oncology - Regenerative Medicine - Genetic diseases | Validation of a production plant | |
| 2016-01-13 | Debiopharm (Switzerland) European Organisation for Research and Treatment of Cancer (EORTC) | triptorelin pamoate 3.75 mg 1-month formulation | salivary gland cancer | clinical research collaboration |
Cancer - Oncology - Rare diseases | Clinical research agreement |
| 2016-01-12 | Diaxonhit (France) CareDx (USA - CA) | AlloMap® | licensing |
Transplantation - Cardiovascular diseases | Licensing agreement | |
| 2016-01-12 | Neurovive Pharmaceutical (Sweden) University of Pennsylvania (USA - PA) | NeuroSTAT® | traumatic brain injury | R&D collaboration |
Traumatology - CNS diseases | R&D agreement |
| 2016-01-12 | Arena Pharmaceuticals (USA - CA) Boehringer Ingelheim (Germany) | drug candidates targeting an undisclosed G protein-coupled receptor (GPCR) | psychiatric diseases | R&D licensing |
Mental diseases | R&D agreement |
| 2016-01-12 | Intellia Therapeutics (USA - MA) | eXtellia Therapeutics | establishment of a new subsidiary in the US |
Autoimmune diseases – Inflammatory diseases - Cancer - Oncology | Establishment of a new subsidiary in the US | |
| 2016-01-12 | BiolineRx (Israel) Merck&Co (USA - NJ) | Keytruda® (pembrolizumab) and BL-8040 | pancreatic cancer | collaboration clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-01-12 | nomination | Autoimmune diseases - Cancer - Oncology | Nomination | |||
| 2016-01-11 | Merck KGaA, Merck Serono (Germany) Threshold Pharmaceuticals (USA) | evofosfamide (TH-302) | soft tissue sarcoma, pancreatic cancer | development |
Cancer - Oncology | Termination of an agreement |
| 2016-01-11 | Innate Pharma (France) Sanofi (France) | bispecific antibody formats engaging natural killer (NK) cells to kill tumor cells through the activating receptor NKp46 | R&D licensing |
Cancer - Oncology | R&D agreement | |
| 2016-01-11 | Sanofi (France) Warp Drive Bio (USA - MA) | SMART™ (Small Molecule Assisted Receptor Targeting) and Genome Mining platforms | collaboration R&D |
Cancer - Oncology - Infectious diseases | Collaboration agreement | |
| 2016-01-11 | Tiziana Life Sciences (UK) | nomination |
Autoimmune diseases - Inflammatory diseases - Digestive diseases - Transplantation | Nomination | ||
| 2016-01-11 | The National Immunotherapy Coalition - Altor Bioscience (USA - FL) Amgen (USA - CA) Celgene (USA - NJ) Etubics (USA - WA) Merck KGaA (Germany) NantKwest (USA - CA) NantWorks (USA - CA) Precision Biologics (USA - TX) | Cancer MoonShot 2020 Program | breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, head and neck cancer, multiple myeloma, sarcoma, pancreatic cancer | collaboration R&D clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-01-11 | Debiopharm (Switzerland) Arbor Pharmaceuticals (USA - GA) | sustained release triptorelin pamoate 22.5 mg 6-month-formulation | central precocious puberty (CPP) | distribution commercialisation |
Rare diseases - Endocrine diseases - Hormonal diseases | Commercialisation agreement |
